相似文献
1
Attenuated therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer.
Oncoimmunology. 2015 Oct 29;5(4):e1104447. doi: 10.1080/2162402X.2015.1104447. eCollection 2016 Apr.
2
Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Cancer Immunol Res. 2015 Aug;3(8):891-901. doi: 10.1158/2326-6066.CIR-14-0235. Epub 2015 Mar 24.
3
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.
Trends Parasitol. 2013 Sep;29(9):431-7. doi: 10.1016/j.pt.2013.07.001. Epub 2013 Aug 5.
4
A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis.
Parasit Vectors. 2021 Dec 11;14(1):601. doi: 10.1186/s13071-021-05032-6.
5
Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.
Med Microbiol Immunol. 2016 Aug;205(4):297-314. doi: 10.1007/s00430-015-0447-5. Epub 2016 Jan 5.
6
A potential cure for tumor-associated immunosuppression by Toxoplasma gondii.
Cancer Rep (Hoboken). 2024 Feb;7(2):e1963. doi: 10.1002/cnr2.1963. Epub 2023 Dec 18.
7
Recombinant attenuated Toxoplasma gondii expressing the Plasmodium yoelii circumsporozoite protein provides highly effective priming for CD8+ T cell-dependent protective immunity against malaria.
J Immunol. 2000 Aug 15;165(4):2084-92. doi: 10.4049/jimmunol.165.4.2084.
8
Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice.
BMC Infect Dis. 2016 Apr 18;16:168. doi: 10.1186/s12879-016-1496-0.
9
Secretion of Rhoptry and Dense Granule Effector Proteins by Nonreplicating Toxoplasma gondii Uracil Auxotrophs Controls the Development of Antitumor Immunity.
PLoS Genet. 2016 Jul 22;12(7):e1006189. doi: 10.1371/journal.pgen.1006189. eCollection 2016 Jul.
10
A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection.
Parasit Vectors. 2015 Sep 30;8:498. doi: 10.1186/s13071-015-1108-7.
引用本文的文献
1
From pathogen to cure: exploring the antitumor potential of Toxoplasma gondii.
Infect Agent Cancer. 2025 Jun 18;20(1):39. doi: 10.1186/s13027-025-00673-z.
2
Parasites revive hope for cancer therapy.
Eur J Med Res. 2024 Oct 5;29(1):489. doi: 10.1186/s40001-024-02057-2.
3
Parasite-enhanced immunotherapy: transforming the "cold" tumors to "hot" battlefields.
Cell Commun Signal. 2024 Sep 26;22(1):448. doi: 10.1186/s12964-024-01822-4.
4
A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.
Front Cell Infect Microbiol. 2024 Jan 11;13:1325144. doi: 10.3389/fcimb.2023.1325144. eCollection 2023.
5
A Novel Protozoa Parasite-Derived Protein Adjuvant Is Effective in Immunization with Cancer Cells to Activate the Cancer-Specific Protective Immunity and Inhibit the Cancer Growth in a Murine Model of Colorectal Cancer.
Cells. 2024 Jan 6;13(2):111. doi: 10.3390/cells13020111.
6
Neospora caninum inhibits tumor development by activating the immune response and destroying tumor cells in a B16F10 melanoma model.
Parasit Vectors. 2022 Sep 23;15(1):332. doi: 10.1186/s13071-022-05456-8.
7
infection possibly reverses host immunosuppression to restrain tumor growth.
Front Cell Infect Microbiol. 2022 Aug 31;12:959300. doi: 10.3389/fcimb.2022.959300. eCollection 2022.
8
Anti-Tumor Effect of Parasitic Protozoans.
Bioengineering (Basel). 2022 Aug 16;9(8):395. doi: 10.3390/bioengineering9080395.
9
Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.
J Cancer Res Clin Oncol. 2022 Oct;148(10):2743-2757. doi: 10.1007/s00432-022-04036-8. Epub 2022 May 12.
10
causes changes in the host's expression of cancer-associated miRNAs.
Oncol Lett. 2022 May;23(5):149. doi: 10.3892/ol.2022.13267. Epub 2022 Mar 15.
本文引用的文献
1
Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Cancer Immunol Res. 2015 Aug;3(8):891-901. doi: 10.1158/2326-6066.CIR-14-0235. Epub 2015 Mar 24.
2
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
Clin Cancer Res. 2015 Aug 15;21(16):3619-30. doi: 10.1158/1078-0432.CCR-14-2334. Epub 2015 Feb 3.
3
Cancer statistics, 2014.
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
4
Non-replicating reverses tumor-associated immunosuppression.
Oncoimmunology. 2013 Nov 1;2(11):e26296. doi: 10.4161/onci.26296. Epub 2013 Oct 9.
5
Follicular helper T-cell memory: establishing new frontiers during antibody response.
Immunol Cell Biol. 2014 Jan;92(1):57-63. doi: 10.1038/icb.2013.68. Epub 2013 Nov 5.
6
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity. 2013 Oct 17;39(4):782-95. doi: 10.1016/j.immuni.2013.10.003.
7
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.
Blood Cancer J. 2013 Sep 6;3(9):e145. doi: 10.1038/bcj.2013.44.
8
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.
Trends Parasitol. 2013 Sep;29(9):431-7. doi: 10.1016/j.pt.2013.07.001. Epub 2013 Aug 5.
9
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
Cancer Res. 2013 Jul 1;73(13):3842-51. doi: 10.1158/0008-5472.CAN-12-1974. Epub 2013 May 23.
10
Advanced-stage pancreatic cancer: therapy options.
Nat Rev Clin Oncol. 2013 Jun;10(6):323-33. doi: 10.1038/nrclinonc.2013.66. Epub 2013 Apr 30.
Zotero 插件